David W. Schulz

4.4k citations

37 papers · 2.9k indexed · h-index 28

Impact in

Behavioral Neuroscience top 0.5%
- Stress Responses and Cortisol
Biological Psychiatry top 1%
- Tryptophan and brain disorders

Papers in

Biological Psychiatry 5
- Tryptophan and brain disorders 5
Behavioral Neuroscience 6
- Stress Responses and Cortisol 6

Co-authors: Richard B. Mailman Anne W. Schmidt Hans Rollema Robert L. Macdonald Lorraine A. Lebel Robert S. Mansbach F. David Tingley Thomas Seeger
Journals: Journal of Medicinal Chemistry (5 papers)Brain Research (4 papers)Journal of Neurochemistry (4 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)
Partner nations: United States Netherlands Germany

In The Last Decade

David W. Schulz

37 papers receiving 2.8k citations

Peers

Countries citing papers authored by David W. Schulz

Since Specialization

Citations

This map shows the geographic impact of David W. Schulz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Schulz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Schulz more than expected).

Fields of papers citing papers by David W. Schulz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Schulz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Schulz. The network helps show where David W. Schulz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David W. Schulz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David W. Schulz Line = papers co-authored together David W. Schulz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Synthesis and SAR of 2-Aryloxy-4-alkoxy-pyridines as Potent Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists Journal of Medicinal Chemistry ·Yuhpyng L. Chen, John P. Braselton, Yuki Miyagoshi, Randall J. Gallaschun, Robert S. Mansbach, Anne W. Schmidt, Thomas Seeger, Jeffrey Sprouse, F. David Tingley, Renee Doherty, David W. Schulz	2008	35
2	Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology ·Hans Rollema, Leslie K. Chambers, J.W. Coe, John R. Glowa, Raymond S Hurst, Lorraine A. Lebel, Yi Lu, Robert S. Mansbach, Robert J. Mather, Elizaveta S. Shmeleva, Steven B. Sands, Eric Schaeffer, David W. Schulz, F. David Tingley, Kathryn Williams	2006	446
3	In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe, Michael G. Vetelino, W.Y. Chen, Michael Wirtz, Paige R. Brooks, Eric P. Arnold, Lorraine A. Lebel, Carol B. Fox, Steven B. Sands, Thomas I. Davis, David W. Schulz, Hans Rollema, F. David Tingley, Brian T. O’Neill	2005	49
4	3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe, Paige R. Brooks, Michael Wirtz, W.Y. Chen, A.A. Koltunova, Michael G. Vetelino, Eric P. Arnold, Lorraine A. Lebel, Carol B. Fox, F. David Tingley, David W. Schulz, Thomas I. Davis, Steven B. Sands, Robert S. Mansbach, Hans Rollema, Brian T. O’Neill	2005	57
5	The Pharmacology of CP‐154,526, a Non‐Peptide Antagonist of the CRH1 Receptor: A Review CNS Drug Reviews ·Patricia A. Seymour, Anne W. Schmidt, David W. Schulz	2003	87
6	Amygdaloid D₁ receptors are not linked to stimulation of adenylate cyclase Synapse ·Sarah K. Leonard, Carl M. Anderson, Jean E. Lachowicz, David W. Schulz, Clinton D. Kilts, Richard B. Mailman	2003	29
7	D₁ Dopamine Receptors in the Amygdala Exhibit Unique Properties Annals of the New York Academy of Sciences ·Sarah K. Leonard, John M. Petitto, Carl M. Anderson, Jenny Jung, Jean E. Lachowicz, David W. Schulz, Clinton D. Kilts, Richard B. Mailman	2003	4
8	Tolcapone increases maximum concentration of levodopa Journal of Neural Transmission ·Thomas Müller, Dirk Woitalla, David W. Schulz, Sören Peters, W. Kuhn, H. Przuntek	2000	27
9	Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat Journal of Pharmacology and Experimental Therapeutics ·Lotta Arborelius, Kelly Skelton, K. V. Thrivikraman, P M Plotsky, David W. Schulz, M J Owens	2000	88
10	Combined Administration of a 5‐Hydroxytryptamine (5‐HT)_1D Antagonist and a 5‐HT Reuptake Inhibitor Synergistically Increases 5‐HT Release in Guinea Pig Hypothalamus In Vivo Journal of Neurochemistry ·Hans Rollema, M.-H. Li, Jeffrey Sprouse, David W. Schulz	1996	70
11	CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proceedings of the National Academy of Sciences ·David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse, John P. Braselton, J.L. Collins, Michael L. Corman, A. DUNAISKIS, Van Dyck Dirk, Anne W. Schmidt, Thomas Seeger, P A Seymour, F. David Tingley, Renee Doherty, E. C. Gruebel Lee, James Heym	1996	308
12	5-cyano-1-[3-(N-methylpyrrolidin-2R-ylmethyl)indol-5-yl] benzimidazole (CP-161,242): A potent, centrally active 5-HT1D receptor agonist and benzodiazepine partial agonist Bioorganic & Medicinal Chemistry Letters ·John E. Macor, David H.A. Blank, Joseph Ullrich, Carol B. Fox, B. Kenneth Koe, Lorraine A. Lebel, Ronald J. Post, Anne W. Schmidt, David W. Schulz, Patricia A. Seymour	1995	1
13	5-[(3-Nitropyrid-2-yl)amino]indoles: Novel Serotonin Agonists with Selectivity for the 5-HT1D Receptor. Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HT1D Receptor Selectivity Journal of Medicinal Chemistry ·John E. Macor, Sajjad Kakaie, Carol B. Fox, Lorraine A. Lebel, Michael E. Newman, Ronald J. Post, Kevin Ryan, Anne W. Schmidt, David W. Schulz, B. Kenneth Koe	1994	27
14	Decline in Response to Nicotine in Aged Rat Striatum: Correlation with a Decrease in a Subpopulation of Nicotinic Receptors Journal of Neurochemistry ·David W. Schulz, George A. Kuchel, Richard E. Zigmond	1993	23
15	3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1) agonist and rotationally restricted phenolic analog of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole Journal of Medicinal Chemistry* ·John E. Macor, Catherine A. Burkhart, James Heym, Jeffrey L. Ives, Lorraine A. Lebel, Michael E. Newman, J.A. Nielsen, Kevin Ryan, David W. Schulz	1990	138
16	Neuronal bungarotoxin blocks the nicotinic stimulation of endogenous dopamine release from rat striatum Neuroscience Letters ·David W. Schulz, Richard E. Zigmond	1989	69
17	Chapter 10 Characterization of neuronal nicotinic receptors using neuronal bungarotoxin Progress in brain research ·Ralph H. Loring, David W. Schulz, Richard E. Zigmond	1989	5
18	Cochicine-induced granule cell loss in rat hippocampus: Selective behavioral and histological alterations Brain Research ·Thomas J. Walsh, David W. Schulz, Hugh A. Tilson, Donald E. Schmechel	1986	110
19	The Multiplicity of the D1 Dopamine Receptor Advances in experimental medicine and biology ·Richard B. Mailman, David W. Schulz, Clinton D. Kilts, Mark H. Lewis, Hans Rollema, Steven D. Wyrick	1986	32
20	Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions Brain Research ·David W. Schulz, Robert L. Macdonald	1981	174

About David W. Schulz

David W. Schulz is a scholar working on Biological Psychiatry, Behavioral Neuroscience, Cellular and Molecular Neuroscience, Endocrinology, Diabetes and Metabolism and Organic Chemistry, having authored 37 papers that have together received 2.9k indexed citations. Recurring topics across this work include Neurotransmitter Receptor Influence on Behavior (12 papers), Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (9 papers), Nicotinic Acetylcholine Receptors Study (8 papers), Stress Responses and Cortisol (6 papers), Synthesis and Biological Evaluation (6 papers), Tryptophan and brain disorders (5 papers) and Hormonal Regulation and Hypertension (5 papers). The work is most often cited by research in Behavioral Neuroscience (585 citations), Biological Psychiatry (271 citations), Cellular and Molecular Neuroscience (1.5k citations), Molecular Biology (1.5k citations) and Psychiatry and Mental health (276 citations). David W. Schulz has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Richard B. Mailman, Anne W. Schmidt, Hans Rollema, Robert L. Macdonald, Lorraine A. Lebel, Robert S. Mansbach, F. David Tingley, Thomas Seeger, P A Seymour and Jeffrey Sprouse. Their work appears in journals such as Journal of Medicinal Chemistry, Brain Research, Journal of Neurochemistry, Journal of Pharmacology and Experimental Therapeutics and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact